Insider Transaction Overview
On July 27, 2026, Martine A. Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), filed a Form 4 with the SEC indicating the sale of approximately $5,038,970 worth of United Therapeutics common stock. The sale consisted of 9,500 shares, each sold at prices ranging from $525.8111 to $535.04 per share.
The shares were held indirectly through family trusts in which Ms. Rothblatt has investment authority. The transactions were executed under a pre‑arranged 10b5‑1 trading plan that was adopted on November 7, 2025. The plan will remain in effect until either 1,734,410 stock options are exercised (all expiring on March 15, 2027) or December 31, 2026, whichever occurs first.
Option Exercise Details
Simultaneously with the sale, Ms. Rothblatt exercised stock options to acquire an additional 9,500 shares of United Therapeutics common stock at an exercise price of $135.42 per share. The exercise generated a gross value of approximately $1,286,489.
Post‑Transaction Holdings
After completing the option exercise and the subsequent sale, Ms. Rothblatt’s family trusts continue to beneficially own 324,443 shares of United Therapeutics common stock and retain 265,410 stock options.
Related Company Developments
In the same reporting period, United Therapeutics received pre‑market approval from the U.S. Food and Drug Administration for its LungFX lung perfusion device, which is intended to evaluate donor lungs ex‑vivo prior to transplantation. Additionally, TD Cowen reiterated its Buy rating on United Therapeutics stock, setting a price target of $675.00 and hosted an investor lunch featuring a leading pulmonologist involved in the TETON studies.
Market Commentary
InvestingPro analysts noted that United Therapeutics shares have delivered a 77 % total return over the past year, but they consider the stock currently overvalued relative to its fair value. The article also referenced unrelated industry news, including BETA Technologies’ first electric aircraft flights under the FAA eVTOL Integration Pilot Program and Raymond James’ earnings expectations for Insmed.